XML 57 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Xcede Technologies, Inc. Joint Venture (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Sep. 30, 2018
Jul. 20, 2018
Nov. 30, 2016
Sep. 30, 2018
Sep. 30, 2017
Debt Conversion, Original Debt, Amount     $ 5,500,000 $ 5,500,000  
Gain (Loss) on Extinguishment of Debt     1,900,000 $ 1,900,000  
Secured Debt, Outstanding Amount $ 500,000 $ 500,000      
Line of Credit Facility, Maximum Borrowing Capacity     1,500,000    
Debt Instrument, Maturity Date   Dec. 31, 2025      
Other Research and Development Expense $ 35,000        
Noncontrolling Interest [Member]          
Debt Conversion, Original Debt, Amount     $ 3,100,000    
Debt Conversion, Converted Instrument, Shares Issued     3,055,551    
Gain (Loss) on Extinguishment of Debt     $ 300,000    
Xcede Technologies inc [Member]          
Debt Instrument, Interest Rate, Stated Percentage     5.00%    
Committed Investment In Cash     $ 1,200,000    
Debt Conversion, Converted Instrument, Shares Issued     5,394,120    
Capital Stock Financing Discount Percentage     20.00%    
Noncontrolling Interest, Description       Noncontrolling interest represents the value of the Series A Preferred and common stock not owned by DBM plus 17% of cumulative losses of Xcede based on the 17% common stock ownership held by noncontrolling interests.  
Equity Method Investment, Ownership Percentage 63.00%     63.00%  
Dynasil Biomedical [Member]          
Debt Conversion, Original Debt, Amount     $ 2,400,000    
Debt Conversion, Converted Instrument, Shares Issued     2,338,569    
Gain (Loss) on Extinguishment of Debt     $ 1,600,000    
External Funding [Member] | Convertible Debt [Member]          
Debt Conversion, Original Debt, Amount     $ 5,200,000    
Secured Promissory Note [Member] | Xcede Technologies inc [Member]          
Debt Instrument, Interest Rate, Stated Percentage     2.00%    
Expense Recognized In Long Term Contract       $ 166,000 $ 306,000
Imputed Interest Rate       5.40%  
Proceeds from Notes Payable     $ 500,000    
Debt Instrument, Maturity Date     Dec. 31, 2025    
Series B Preferred Stock [Member]          
Preferred Stock, Liquidation Preference Per Share $ 1.27     $ 1.27  
Preferred Stock, Liquidation Preference, Value $ 1,500,000     $ 1,500,000  
Series A Preferred Stock [Member]          
Debt Conversion, Converted Instrument, Amount       $ 3,600,000  
Preferred Stock, Liquidation Preference Per Share $ 1.016     $ 1.016  
Preferred Stock, Liquidation Preference, Value $ 5,500,000     $ 5,500,000  
Series A Preferred Stock [Member] | Noncontrolling Shareholders [Member]          
Preferred Stock, Liquidation Preference, Value 3,100,000     3,100,000  
Series A Preferred Stock [Member] | Dynasil Biomedical [Member]          
Preferred Stock, Liquidation Preference, Value $ 2,400,000     $ 2,400,000